CELLULAR STORIES / CLINICAL EVIDENCE

Daraxonrasib in metastatic pancreatic cancer

RASolute 302 | Overall randomized population | NCT06625320

A The comparison

500 participants

Progression after one systemic regimen

Metastatic pancreatic adenocarcinoma; ECOG 0 or 1

1:1

DARAXONRASIB

248 participants

300 mg orally once daily

PHYSICIAN CHOICE

252 participants

Standard chemotherapy

Randomized, open-label, multicenter study. Results below describe this trial population, not individual outcomes.

B Overall survival

Median months

Daraxonrasib

13.2

95% CI: 10.0 to NE months

Chemotherapy

6.7

95% CI: 5.8 to 8.0 months

HR 0.40 (0.30-0.53)

Hazard ratio with 95% confidence interval

C Progression-free survival

Median months

Daraxonrasib

7.2

95% CI: 5.7 to 7.5 months

Chemotherapy

3.6

95% CI: 2.9 to 4.2 months

HR 0.49 (0.38-0.64)

Hazard ratio with 95% confidence interval

D Objective response

Participants with objective response (%)

Daraxonrasib

30%

95% CI: 25 to 36%

Chemotherapy

11%

95% CI: 7 to 15%

BICR assessment

Reported rates; no patient counts inferred

E Read the endpoints correctly

These are summary estimates, not survival curves.

Median survival and response answer different questions.
A hazard ratio is not an individual chance of benefit.
PFS and response were assessed by blinded central review.

F Benefit comes with treatment risks

Selected label warnings

Skin and soft-tissue toxicity; stomatitis; diarrhea; gastrointestinal perforation; ILD/pneumonitis; fetal harm. Consult the full prescribing information for safety.

Source: RASONQUE prescribing information (August 2026), Section 14, Table 6; Sections 5-6 for safety.

FDA approval notice, 26 August 2026. CI = confidence interval. NE = not estimable. BICR = blinded independent central review.

Independent scientific communication example. All values transcribed from the sources; bar lengths encode the reported point estimates.